Skip to content

Debt Maturity - 2027 at other companies

Morgan Stanley logo
Morgan StanleyMS
$115.47B+14.7%
U.S. Bancorp logo
U.S. BancorpUSB
$11.65B-13.6%
Morgan Stanley logo
Morgan StanleyMS
$20.02B-9.8%
U.S. Bancorp logo
U.S. BancorpUSB
$4.26B-4.8%
Mondelez International logo
Mondelez InternationalMDLZ
$1.74B+46.6%
Mondelez International logo
Mondelez InternationalMDLZ
$2.12B+34.6%

Other financials

Income statement

See full
Revenue$311.3M+127%
Gross profit$43.5M
Operating income-$92.7M-16.9%
Net income-$94.4M-28.9%
EPS (diluted)-$3.25-24.5%

Balance sheet

See full
Cash & equivalents$232.2M+23.1%
Total debt$377.3M+187%
Total equity$543.5M-23.5%
Total assets$1.2B+23.1%

Cash flow

See full
Operating cash flow-$167.4M-88.4%
CapEx$3.8M
Free cash flow-$171.3M-92.7%

Valuation

See full
Market cap$11.66B+64.2%
Enterprise value$11.81B+67.5%
P/S10.3×-12.1×

Profitability

See full
Gross margin96.5%
Operating margin-27.7%-12.2pp
Net margin-27.3%-12.0pp
FCF margin-59.8%-29.6pp

Returns & leverage

See full
Return on equity-49.3%-0.8pp
Debt / equity0.7×+0.5×
Current ratio3.5×-2.4×

Where this comes from

Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree.

The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Madrigal Pharmaceuticals, Inc.'s debt maturity - 2027.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Madrigal Pharmaceuticals, Inc.'s debt maturity - 2027?
Madrigal Pharmaceuticals, Inc. (MDGL) reported debt maturity - 2027 of $29.98M in Q1 2026.
How has Madrigal Pharmaceuticals, Inc.'s debt maturity - 2027 changed year-over-year?
Madrigal Pharmaceuticals, Inc.'s debt maturity - 2027 decreased by 76.2% year-over-year, from $126.02M to $29.98M.